Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin

Chirality

Volumn 24, Issue 2, 2012, Pages 174-180

  Yuan, Fang ^a   Chen, Xiaojia ^a   Liu, Yanan ^a,b   Zhang, Tingting ^a   Sun, Dongdong ^a   Liu, Jie ^a  

^a JINAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticancer activity; Apoptosis; Binding; Bovine serum albumin (BSA); Ru(II) complex

Indexed keywords

BOVINE SERUM ALBUMIN; RUTHENIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CELL VIABILITY; CHIRALITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; ISOMER; MOLECULAR INTERACTION; NONHUMAN; NONPHOTOCHEMICAL QUENCHING; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CIRCULAR DICHROISM; DNA FRAGMENTATION; HUMANS; MICROSCOPY, FLUORESCENCE; ORGANOMETALLIC COMPOUNDS; PROTEIN STRUCTURE, SECONDARY; RUTHENIUM; SERUM ALBUMIN, BOVINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84855516369     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.21980     Document Type: Article

References (47)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-584. (Pubitemid 47106628)
2. Bruijnincx PC, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 2008;12:197-206.
3. Alama A, Tasso B, Novelli F, Sparatore F. Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov Today 2009;14:500-508.
4. Che CM, Huang JS. Ruthenium and osmium porphyrin carbene complexes: synthesis, structure, and connection to the metal-mediated cyclopropanation of alkenes. Coord Chem Rev 2002;231:151-164.
5. Brabec V, Novakova O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Update 2006;9:111-122. (Pubitemid 44279519)
6. Liu J, Zheng WJ, Shi S, Tan CP, Chen JC, Zheng KC, Ji LN. Synthesis, antitumor activity and structure - activity relationships of a series of Ru(II) complexes. J Inorg Biochem 2008;102:193-202.
7. Zava O, Zakeeruddin SM, Danelon C, Vogel H, Gratzel M, Dyson PJ. A cytotoxic ruthenium Tris(Bipyridyl) complex that accumulates at plasma membranes. ChemBioChem 2009;10:1796-1800.
8. Linares F, Galindo MA, Galli S, Romero MA, Navarro JA, Barea E. Tetranuclear coordination assemblies based on half-sandwich ruthenium(II) complexes: noncovalent binding to DNA and cytotoxicity. Inorg Chem 2009;48:7413-7420.
9. Xu L, Zhang D, Huang J, Deng M, Zhang M, Zhou X. High fluorescence selectivity and visual detection of G-quadruplex structures by a novel dinuclear ruthenium complex. Chem Commun 2010;46:743-745.
10. Chen T, Liu Y, Zheng WJ, Liu J, Wong YS. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. Inorg Chem 2010;49:6366-6368.
11. Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Curr Top Med Chem 2004;4:1525-1535. (Pubitemid 39662663)
12. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem 2006;100:891-904. (Pubitemid 44308176)
13. Bratsos I, Jedner S, Gianferrara T, Alessio E. Ruthenium anticancer compounds: challenges and expectations. Chimia 2007;61:692-697.
14. Meng X, Leyva ML, Jenny M, Gross I, Benosman S, Fricker B, Harlepp S, Hébraud P, Boos A, Wlosik P, Bischoff P, Sirlin C, Pfeffer M, Loeffler JP, Gaiddon C. A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP. Cancer Res 2009;69:5458-5466.
15. Barton JK. Metals and DNA: molecular left-handed complements. Science 1986;233:727-734. (Pubitemid 16016223)
16. Pyle AM, Barton JK. Probing nucleic acids with transition metal complexes. Progr Inorg Chem 1990;38:413-475.
17. Zeglis BM, Pierre VC, Barton JK. Metallointercalators and metalloinsertors. Chem Commun 2007;44:4565-4579.
18. Erkkila KE, Odom DT, Barton JK. Recognition and reaction of metallointercalators with DNA. Chem Rev 1999;99:2777-2795.
19. Friedman AE, Chambron JC, Sauvage JP, Turro NJ, Barton JK. Molecular "light switch" for DNA Ru(bpy)2(dppz)21. J Am Chem Soc 1990;112:4960-4962. (Pubitemid 20285921)
20. Janaratne TK, Yadav A, Ongeri F, MacDonnell FM. Preferential DNA cleavage under anaerobic conditions by a DNA-binding ruthenium dimer. Inorg Chem 2007;46:3420-3422.
21. Deshpande MS, Kumbhar AA, Kumbhar AS. Hydrolytic cleavage of DNA by a ruthenium(II) polypyridyl complex. Inorg Chem 2007;46:5450-5452.
22. Gao F, Chao H, Wang JQ, Yuan YX, Sun B, Wei YF, Peng B, Ji LN. Targeting topoisomerase II with the chiral DNA-intercalating ruthenium(II) polypyridyl complexes. J Biol Inorg Chem 2007;12:1015-1027. (Pubitemid 47353546)
23. Du KJ, Wang JQ, Kou JF, Li GY, Wang LL, Chao H, Ji LN. Synthesis, DNA-binding and topoisomerase inhibitory activity of ruthenium(II) polypyridyl complexes. Eur J Med Chem 2011;46:1056-1065.
24. Peters T Jr. All about albumin: biochemistry, genetics, and medical applications. San Diego: Academic Press; 1996.
25. Olson RE, Christ DD. Plasma protein binding of drugs. Annu Rep Med Chem 1996;31:327-336.
26. Zhang Y, Wilcox DE. Thermodynamic and spectroscopic study of Cu(II) and Ni(II) binding to bovine serum albumin. J Biol Inorg Chem 2002;7:327-337. (Pubitemid 36056385)
27. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev 2006;106:2224-2248.
28. Sulkowska A, Bojko B, Równicka J, Sulkowski W. Competition of drugs to serum albumin in combination therapy. Biopolymers 2004;74:256-262. (Pubitemid 38728941)
29. Chen T, Mei WJ, Wong YS, Liu J, Liu Y, Xie HS, Zheng WJ. Chiral ruthenium polypyridyl complexes as mitochondria-targeted apoptosis inducers. Med Chem Commun 2010;1:73-75.
30. Mei WJ, Wang N, Liu YJ, Ma YZ, Wang DY, Liang BX. Studies on cytotoxic and DNA-binding properties of two ruthenium(II) complexes of a substituted phenanthroline ligand. Transit Met Chem 2008;33:499-503.
31. 2+. Chirality 2009;21:276-283.
32. Khan NU, Pandya N, Kureshy RI, Abdi SH, Agrawal S, Bajaj HC, Pandya J, Gupte A. Synthesis, characterization, DNA binding and cleavage studies of chiral Ru(II) salen complexes. Spectrochim Acta Part A 2009;74:113-119.
33. 2+ (L = o-mopip and p-mopip). J Inorg Biochem 2006;100:385-395.
34. Cotter TG, Martin SJ. Techniques in apoptosis: a user's guide. London: Portland Press Ltd; 1996. p 10-11.
35. 2Cl]Cl and its heterometallic derivatives. Chem Biol Interact 2010;183:349-356.
36. Chen T, Wong YS. Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. J Agric Food Chem 2008;56:10574-10581.
37. Chen T, Wong YS. Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci 2008;65:2763-2775.
38. Cohen GM, Sun XM, Fearnhead H, MacFarlane M, Brown DG, Snowden RT, Dinsdale D. Formation of large molecular weight fragments of DNA is a key committed step of apoptosis in thymocytes. J Immunol 1994;153:507-516. (Pubitemid 24206280)
39. Tan CP, Liu J, Li H, Zheng WJ, Shi S, Chen LM, Ji LN. Differences in structure, physiological stability, electrochemistry, cytotoxicity, DNA and protein binding properties between two Ru(III) complexes. J Inorg Biochem 2008;102:347-358.
40. Dimiza F, Perdih F, Tangoulis V, Turel I, Kessissoglou DP, Psomas G. Interaction of copper(II) with the non-steroidal anti-inflammatory drugs naproxen and diclofenac: synthesis, structure, DNA- and albumin-binding. J Inorg Biochem 2011;105:476-489.
41. Peters T Jr. Serum albumin. Adv Protein Chem 1985;37:161-245.
42. Lakowicz JR, Weber G. Quenching of fluorescence by oxygen-a probe for structural fluctuations in macromolecules. Biochemistry 1973;12:4161-4170.
43. Lakowicz JR. Principles of fluorescence spectroscopy. New York: Plenum Press; 1999. p237-265.
44. Papadopoulou A, Green RJ, Frazier RA. Interaction of flavonoids with bovine serum albumin: a fluorescence quenching study. J Agric Food Chem 2005;53:158-163. (Pubitemid 40066484)
45. Jiang CQ, Gao MX, He JX. Study of the interaction between terazosin and serum albumin synchronous fluorescence determination of terazosin. Anal Chim Acta 2002;452:185-189.
46. Hu YJ, Liu Y, Wang JB, Xiao XH, Qu SS. Study of the interaction between monoammonium glycyrrhizinate and bovine serum albumin. J Pharm Biomed Anal 2004;36:915-919. (Pubitemid 39469437)
47. Chen YH, Yang JT. A new app roach to the calculation of secondary structures of globular proteins by optical rotatory dispersion and circular dichroism. Biochem Biophys Res Commun 1971;44:1285-1291.